STAT

Donations of $4,500 overdose antidote were PR gold for drug maker — but some kits were close to expiring

As Kaleo raised the price of its Evzio overdose antidote, its donations to police agencies earned it a PR boon. But some of the donated naloxone was close to its…
Source: AP Photo/Cliff Owen

DUNWOODY, Ga. — Three years ago, with the opioid epidemic taking off, police officers in this affluent Atlanta suburb noticed an uptick in overdoses. Sgt. Robert Parsons rushed to equip his fellow officers with a lifesaving tool: the opioid antidote naloxone.

He stumbled across a drug company that was donating free cartons of naloxone auto-injectors to police agencies, and placed an order online. Within months, he had revived a man. But the following spring, when another batch of naloxone arrived, he was surprised to find that the injectors were set to expire in four months.

“You don’t know what you’re getting until the boxes show up,” said Parsons, the Dunwoody department’s naloxone coordinator. “You might as well begin filling out the paperwork [right away] to get them replaced.”

The drug charity program has generated a public relations windfall for Kaleo since its Evzio auto-injectors hit the market four years ago. The Virginia-based company claims to have donated more than 330,000 auto-injectors to police officers, health workers, and nonprofit groups since 2014 — saving 5,000 lives.

Company executives have traveled the country to shake hands with local officials and speak at from President Trump during a speech this spring.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks